Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

By Nikita Chaurasia  Date: 2021-01-04

Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

Indian pharmaceutical company Cadila Healthcare Limited, commonly known as Zydus Cadila, has made it to the headlines after receiving the approval of the DCGI (Drugs Controller General of India) for the Phase 3 clinical trials of its Coronavirus vaccine ZyCoV-D.

For the uninitiated, ZyCoV-D is a plasmid DNA, which translates into viral proteins when introduced into the host cells in order to trigger a robust immune response, facilitated by the humoral and cellular arms of the human immune system.

The Phase 3 trial round will include around 30000 volunteers. Sources confirmed that the company plans on initiating the launch as well as administration of the vaccine in the first quarter of the next financial year if the trial results are in its favor.

Reportedly, ZyCoV-D was proven to be well-tolerated, safe and immunogenic in its phase-1 and phase-2 clinical trials. It is also worth mentioning that the phase-2 trial round was conducted on around 1000 volunteers and included a randomized, multi-centric, dose-escalation double-blind placebo-controlled study.

The phase-2 trials were reviewed by an independent DSMB (Data Safety Monitoring Board) and the reports of the safety outcomes were submitted to the CDSCO (Central Drugs Standard Control Organization). Zydus Cadila then called for the DCGI approval after the phase-2 trials concluded positive outcomes.

Chairman of Zydus Group, Pankaj Patel was reported saying that the DCGI approval marks a significant milestone for the company’s vaccine development program. The phase-3 trials will ascertain the efficacy of ZyCoV-D in the treatment of Covid-19, he added.

The introduction of ZyCoV-D, developed in the company's Ahmedabad-based Vaccine Technology Centre, has paved the way for the establishment of a DNA vaccine platform in India, sources claimed. This platform has proven to improve vaccine stability and hence requires lower cold chain storage.

Moreover, Zydus Cadila has reportedly employed around 300 scientists to conduct comprehensive research on the vaccine, with around 1,400 researchers working on pharmaceutical technologies, biologicals and chemical entities (NCEs).

Source credits –

https://www.business-standard.com/article/current-affairs/zydus-gets-dcgi-nod-for-conducting-phase-3-clinical-trials-of-zycov-d-121010300466_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...